A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers caused by the human papillomavirus and one of the ...

When topline phase III data was released in November, hinting at the potential of success, Jefferies analyst Akash Tiwari ...

Merck & Co. (MRK) releases positive phase three data for its injectable-form cancer drug Keytruda. Yahoo Finance Senior ...

The HPV vaccine, called Gardasil-9 — which has no live virus and is completely non-infectious — protects against the six types of HPV most likely to cause cancer, Eckert says. (These are strains 6, 11 ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

Despite this potential, the stock has fallen by 25% in the past 12 months -- so is it a bargain buy right now? During the ...

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and ...

We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher. In this article, we are ...

If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss ...

Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial ...

Merck (NYSE:MRK) has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vaccines market. Despite ...